| Topic | Key finding | Evidence level | Notes / unknowns |
|---|---|---|---|
| Disease identity / identifier | MRPL44-related disease is a nuclear-encoded mitochondrial translation disorder described as infantile mitochondrial/hypertrophic cardiomyopathy and as part of combined oxidative phosphorylation deficiency; Open Targets lists **MONDO:0014162** “infantile hypertrophic cardiomyopathy due to MRPL44 deficiency” and association to broader **combined oxidative phosphorylation deficiency** (**MONDO:0000732**) (pqac-00000015, pqac-00000011, pqac-00000013) | Review/database + direct literature linkage | A disease-specific OMIM/Orphanet identifier was not directly available in retrieved source text; avoid asserting one without primary confirmation. |
| Causal gene and inheritance | Causal gene: **MRPL44** (mitochondrial ribosomal protein L44), a component of the mitochondrial large ribosomal subunit; reported disease mechanism is **biallelic/homozygous** pathogenic variation, consistent with **autosomal recessive** inheritance (pqac-00000013, pqac-00000005) | Direct human + review | Direct segregation details for all published families were not accessible in full text here; AR inference is supported by homozygous cases and review summaries. |
| Established variants | Directly retrieved variant from iPSC/model study: **c.467T>G, p.Leu156Arg (p.L156R)** in homozygous state (pqac-00000005, pqac-00000010). Reviews also summarize a homozygous **p.Leu156Arg** MRPL44 mutation uncovered by exome sequencing in affected siblings (pqac-00000013). | Direct human + iPSC preprint + review | Additional MRPL44 variants were mentioned in unavailable or secondary sources, but should be treated as unconfirmed here because the primary full text was not available in retrieved context. |
| Core phenotypes | Core phenotype is **neonatal/infantile hypertrophic cardiomyopathy**; broader spectrum may include slowly progressive **multisystem disease** involving skeletal muscle, liver, kidney, and central nervous system in later reports/review summaries (pqac-00000011, pqac-00000013, pqac-00000007) | Direct human + review | Detailed per-patient frequencies, sex ratio, and full HPO-level breakdown were not available from accessible primary text. |
| Molecular defect | MRPL44 deficiency causes impaired **mitochondrial translation**, defective **large mitoribosomal subunit assembly/stability**, reduced **16S rRNA stability**, and **OXPHOS deficiency** with particular impact on **complex IV**; in cardiomyocytes, complex I protein reduction, increased mtDNA copy number, and stress-response activation were observed (pqac-00000013, pqac-00000005, pqac-00000007) | Patient-cell + iPSC preprint + review | The exact hierarchy of complex defects across tissues remains incompletely resolved from accessible primary evidence. |
| Diagnosis | Diagnostic approaches reported or implied include **exome sequencing/genomic sequencing** for MRPL44, functional follow-up in **patient fibroblasts** or **iPSC-derived cardiomyocytes**, and mitochondrial disease workup focused on **respiratory chain/OXPHOS defects** and cardiomyopathy assessment (pqac-00000013, pqac-00000005, pqac-00000006) | Direct human + patient-cell + iPSC preprint | No disease-specific standardized diagnostic criteria, biomarker threshold, or screening algorithm was identified in retrieved sources. |
| Treatment / trials | No MRPL44-specific disease-modifying therapy or interventional clinical trial was identified; management appears supportive and phenotype-directed as for mitochondrial cardiomyopathy. A review of severe childhood cardiomyopathies noted that cardiac findings in some mitochondrial cardiomyopathies including **MRPL44** may stabilize in a minority who survive early childhood (pqac-00000009, pqac-00000007) | Review/contextual clinical evidence | No MRPL44-targeted pharmacotherapy, gene therapy, or registered MRPL44-specific trial was found in retrieved evidence. |
| Epidemiology | **Ultra-rare** disorder with only a small number of published families/cases implied across foundational and later reports; no prevalence or incidence estimate was retrieved (pqac-00000013, pqac-00000015) | Review/database | Population prevalence, carrier frequency, founder effects, and sex distribution are unknown from accessible evidence. |
| Models | **Patient fibroblasts**: reduced MRPL44 levels and mitoribosome/OXPHOS defects summarized in reviews; **patient-derived iPSC-cardiomyocytes** with homozygous p.L156R show nutrient-dependent pathology, increased mtDNA copy number, reduced complex I protein, ISRmt/ER stress, and lipid droplet accumulation in fatty-acid conditions (pqac-00000013, pqac-00000005, pqac-00000007, pqac-00000010) | Patient-cell + iPSC preprint | No dedicated animal model of MRPL44 deficiency was directly retrieved in accessible evidence; broader mouse-model reviews discuss mitochondrial translation disease generally, not a specific MRPL44 animal model here. |


*Table: This table condenses the most reliable disease-specific findings currently retrievable for MRPL44 deficiency, separating direct human and cellular evidence from review/database support. It also highlights where identifiers, epidemiology, and treatment data remain unknown or insufficiently documented.*